Company: CMND
Filing Date: 2025-11-17
Form Type: 424B5
Source: 0001213900-25-111233
Chunk: 23

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-17
Form: 424B5
Chunk 23
---
 | the timing and focus of our future preclinical studies and clinical trials, and the reporting of data from those studies and trials; |

| ● | the size of the market opportunity for our future product candidates, including our estimates of the number of patients who suffer from the diseases we are targeting; |

| ● | the success of competing therapies that are or may become available; |

| ● | the beneficial characteristics, safety, efficacy and therapeutic effects of our future product candidates, as well as the potential healthcare costs saved through utilizing our future product candidates; |

| ● | the ability of our future product candidates to address needs not currently addressed by the psychedelic industry; |

| ● | the ability of our future product candidates to address needs not currently addressed by the psychedelic industry; |

| ● | our ability to obtain and maintain regulatory approval of our future product candidates; |

| ● | our plans relating to the further development of our future product candidates, including additional disease states or indications we may pursue; |

| ● | existing regulations and regulatory developments in the United States and other jurisdictions; |

| ● | our plans and ability to obtain or protect intellectual property rights, including extensions of patent terms where available and our ability to avoid infringing the intellectual property rights of others; |

| ● | the ability of our management team to oversee our drug research programs; |

<div align='center'>S-10</div>

| ● | the need to hire additional personnel and our ability to attract and retain such personnel; |

| ● | our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; |

| ● | our dependence on third parties; |

| ● | our ability to compete with other companies who offer products that address similar issues that our future product candidates will address; |

| ● | our financial performance; |

| ● | the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements; |

| ● | our ability to generate revenue and profit margin under our anticipated contracts which is subject to certain risks; |

| ● | difficulties in our partners’ ability to recruit and retain qualified physicians and other healthcare professionals, and enforce our non-compete agreements with our physicians; |

| ● | our ability to restructure our operations to comply with future changes in government regulation; |

| ● | our ability to maintain the listing of our Common Shares on Nasdaq; |

| ● | security, political and economic instability in the Middle East that could harm our business, including due to the